International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1043-1048 , 15 March 2009

Stereotactic Body Radiotherapy for Localized Prostate Cancer: Interim Results of a Prospective Phase II Clinical Trial

  • Christopher R. King, Ph.D., M.D.

      Affiliations

    • Department of Radiation Oncology, Division of Urologic Oncology, Stanford University School of Medicine, Stanford, CA
    • Corresponding Author InformationReprint requests to: Christopher R. King, Ph.D., M.D., Department of Radiation Oncology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305. Tel: (650) 736-0698; Fax: (650) 725-8231
    • ,
  • James D. Brooks, M.D.

      Affiliations

    • Department of Urology, Division of Urologic Oncology, Stanford University School of Medicine, Stanford, CA
    • ,
  • Harcharan Gill, M.D.

      Affiliations

    • Department of Urology, Division of Urologic Oncology, Stanford University School of Medicine, Stanford, CA
    • ,
  • Todd Pawlicki, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Division of Urologic Oncology, Stanford University School of Medicine, Stanford, CA
    • ,
  • Cristian Cotrutz, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Division of Urologic Oncology, Stanford University School of Medicine, Stanford, CA
    • ,
  • Joseph C. Presti Jr., M.D.

      Affiliations

    • Department of Urology, Division of Urologic Oncology, Stanford University School of Medicine, Stanford, CA

Received 4 April 2008 ,Revised 19 May 2008 ,Accepted 27 May 2008.

References 

  1. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962–1984). Urology. 1990;36:107–111
  2. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  3. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1013–1015
  4. Duchesne GM, Peters LJ. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  5. Dasu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol. 2007;19:289–301
  6. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated vs. conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083
  7. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–6138
  8. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  9. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254–1259
  10. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized prostate disease: First clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105
  11. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316
  12. Martinez A, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169:974–979
  13. Yoshioka Y, Nose T, Yoshida K, et al. High-dose rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys. 2003;56:213–220
  14. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;56:1093–1104
  15. Greene FL, Page DL, Flemming ID, et al. AJCC manual for staging cancer. 6th ed.. New York: Springer Verlag; 2002;p. 309–313
  16. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–1564
  17. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  18. Common toxicity criteria. National Institutes of Health publication (version 2.0) 1998.
  19. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  20. Guerrero M, Li XA. Halftime for repair of sublethal damage in normal bladder and rectum: An analysis of clinical data from cervix brachytherapy. Phys Med Biol. 2006;51:4063–4071
  21. Crook J, Gillan C, Yeung I, et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;69:426–433
  22. Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: A multiinstitutional pooled analysis. Cancer. 2006;107:1496–1502

 Conflict of interest: none.

PII: S0360-3016(08)02459-0

doi: 10.1016/j.ijrobp.2008.05.059

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 4 , Pages 1043-1048 , 15 March 2009

Article Tools

* Image Usage & Resolution